Lisata Therapeutics announces first patient treated with second-line CCA

Lisata Therapeutics announced treatment of the first patient in the second-line cholangiocarcinoma, CCA, cohort of the BOLSTER trial. This follows the recently announced successful completion of enrollment in the first-line CCA cohort. “We are pleased to announce the dosing of the first patient in the second-line cholangiocarcinoma cohort of the BOLSTER trial,” said Kristen K. Buck, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Lisata. “Initiation of this cohort is based on the recommendation of investigators from our BOLSTER study’s first-line cholangiocarcinoma cohort to evaluate certepetide in patients who progressed after being treated with first-line standard-of-care therapy alone. We are excited to expand the evaluation of certepetide in this broadened cholangiocarcinoma population with the goal of improving outcomes for these patients in dire need.”